.png){kind=icon}
.png){kind=icon}
Return
Low dose radiotherapy-induced tumor-preferential antigens enhance antibody-drug conjugate efficacy in solid tumors
.png){kind=icon}
OA
AI
Y
Y
Y
T
L
J
Y
Y
Y
P
P
DOI：10.1016/j.neo.2026.101335.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Antibody-drug conjugate (ADC) efficacy in solid tumors is often limited by low or heterogeneous antigen expression. Here, we investigated low-dose radiotherapy (LDRT) as a noninvasive sensitization strategy to enhance tumor surface antigen expression and improve ADC activity. Transcriptomic profiling and flow cytometry identified ICAM1 as the most strongly radiation-inducible antigen after 2 Gy irradiation, showing an approximately 4-fold increase and exceeding several established ADC targets. Mechanistic studies revealed that radiation-induced reactive oxygen species (ROS) and oxidative stress signaling upregulated ICAM1, enhanced antibody internalization, and improved ICAM1-targeted ADC delivery. In xenograft models, LDRT combined with ICAM1-targeted ADCs achieved >70% tumor growth inhibition with minimal toxicity. Transcriptomic and immunohistochemical (IHC) staining analyses further showed that LDRT induced recruitment of immunosuppressive CCL8high M2-like tumor-associated macrophages, whereas ADC-mediated bystander killing attenuated this adaptive feedback and promoted a more immunoactive tumor microenvironment. Together, these findings support LDRT as a clinically translatable strategy to increase ICAM1 expression, overcome antigen-low barriers, and enhance ADC efficacy in refractory solid tumors.
Keywords:
Antibody–drug conjugates
Low-dose radiotherapy
ICAM1 upregulation
Tumor antigen modulation
Bystander killing
Tumor microenvironment
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.7
Papers:
2.8K
Citations:
8.0K
Organization
Cited Papers